Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 381

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 381
---
       — |   |
| Maturities of marketable securities                                         |     |                           |   2,500 |   |     |      |  10,656 |   |
| Net cash provided by (used in) investing activities                         |     |                           |   4,989 |   |     |      | (19,178 | ) |
| Financing Activities                                                        |     |                           |         |   |     |      |         |   |
| Proceeds from issuance of redeemable convertible Series C preferred stock   |     |                           |       — |   |     |      |  40,000 |   |
| Payment of issuance costs                                                   |     |                           |       — |   |     |      |  (1,708 | ) |
| Proceeds from exercise of warrants and options                              |     |                           |       — |   |     |      |       3 |   |
| Net cash provided by financing activities                                   |     |                           |       — |   |     |      |  38,295 |   |
| Net decrease in cash, cash equivalents and restricted cash                  |     |                           |  (8,743 | ) |     |      |  (6,233 | ) |
| Cash, cash equivalents and restricted cash, beginning of period             |     |                           |  23,476 |   |     |      |  14,979 |   |
| Cash, cash equivalents and restricted cash, end of period                   |     | $                         |  14,733 |   |     | $    |   8,746 |   |
| Supplemental Disclosures of Noncash Investing and Financing Information     |     |                           |         |   |     |      |         |   |
| Right-of-use                                                                
 assets obtained in exchange for operating lease liabilities                 |     | $                         |       — |   |     | $    |   2,405 |   |
| Leasehold improvements paid by lessor                                       |     | $                         |       — |   |     | $    |   1,158 |   |

See accompanying notes to the unaudited condensed financial statements. F-42

LB Pharmaceuticals Inc

Notes to Condensed Financial Statements

(Unaudited)

1. Business Overview

LB Pharmaceuticals Inc (the
“Company” or “LB”) was incorporated under the laws of the State of Delaware in September 2015 and is headquartered in New York, New York.

The